Click here to get full coverage on SGMT News Today: China’s NMPA Accepts New Acne Drug - Meyka

SGMT News Today: China’s NMPA Accepts New Acne Drug  Meyka

SGMT News Today: China’s NMPA Accepts New Acne Drug - Meyka

Click here to get full coverage on Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan

Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA  Stock Titan

Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan

Click here to get full coverage on Insider Sale: Executive Chairman of $SGMT Sells 37,688 Shares | SGMT Stock News - Quiver Quantitative

Insider Sale: Executive Chairman of $SGMT Sells 37,688 Shares | SGMT Stock News  Quiver Quantitative

Insider Sale: Executive Chairman of $SGMT Sells 37,688 Shares | SGMT Stock News - Quiver Quantitative

Click here to get full coverage on While institutions own 29% of Sagimet Biosciences Inc. (NASDAQ:SGMT), individual investors are its largest shareholders with 45% ownership - Yahoo Finance

While institutions own 29% of Sagimet Biosciences Inc. (NASDAQ:SGMT), individual investors are its largest shareholders with 45% ownership  Yahoo Finance

While institutions own 29% of Sagimet Biosciences Inc. (NASDAQ:SGMT), individual investors are its largest shareholders with 45% ownership - Yahoo Finance

Click here to get full coverage on Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha

Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts  Seeking Alpha

Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha

Click here to get full coverage on Clear Street Initiates Coverage of Sagimet Biosciences (SGMT) with Buy Recommendation - Nasdaq

Clear Street Initiates Coverage of Sagimet Biosciences (SGMT) with Buy Recommendation  Nasdaq

Clear Street Initiates Coverage of Sagimet Biosciences (SGMT) with Buy Recommendation - Nasdaq

Click here to get full coverage on Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Sahm

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Click here to get full coverage on Sagimet’s License Partner Ascletis Announced Acceptance of - GlobeNewswire

Sagimet’s License Partner Ascletis Announced Acceptance of  GlobeNewswire

Sagimet’s License Partner Ascletis Announced Acceptance of - GlobeNewswire

Click here to get full coverage on Sagimet Biosciences Inc.'s (NASDAQ:SGMT) market cap dropped US$22m last week; individual investors who hold 46% were hit as were institutions - simplywall.st

Sagimet Biosciences Inc.'s (NASDAQ:SGMT) market cap dropped US$22m last week; individual investors who hold 46% were hit as were institutions  simplywall.st

Sagimet Biosciences Inc.'s (NASDAQ:SGMT) market cap dropped US$22m last week; individual investors who hold 46% were hit as were institutions - simplywall.st

Click here to get full coverage on Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative

Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China  Quiver Quantitative

Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative

Click here to get full coverage on Ascletis acne drug denifanstat (SGMT) NDA accepted by China NMPA after Phase III success - Stock Titan

Ascletis acne drug denifanstat (SGMT) NDA accepted by China NMPA after Phase III success  Stock Titan

Ascletis acne drug denifanstat (SGMT) NDA accepted by China NMPA after Phase III success - Stock Titan

Click here to get full coverage on All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy - Nasdaq

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy  Nasdaq

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy - Nasdaq

Click here to get full coverage on $SGMT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$SGMT stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$SGMT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Sagimet (NASDAQ: SGMT) unveils AASLD posters; 34% two-stage fibrosis improvement vs 4% - Stock Titan

Sagimet (NASDAQ: SGMT) unveils AASLD posters; 34% two-stage fibrosis improvement vs 4%  Stock Titan

Sagimet (NASDAQ: SGMT) unveils AASLD posters; 34% two-stage fibrosis improvement vs 4% - Stock Titan

Click here to get full coverage on Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks - Nasdaq

Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks  Nasdaq

Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks - Nasdaq

Click here to get full coverage on New Analyst Forecast: $SGMT Given 'Buy' Rating | SGMT Stock News - Quiver Quantitative

New Analyst Forecast: $SGMT Given 'Buy' Rating | SGMT Stock News  Quiver Quantitative

New Analyst Forecast: $SGMT Given 'Buy' Rating | SGMT Stock News - Quiver Quantitative

Click here to get full coverage on What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? - Yahoo Finance

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?  Yahoo Finance

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Click here to get full coverage on Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT)  Seeking Alpha

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha

Click here to get full coverage on 3 Investor Conferences: Sagimet Biosciences to Present Oct–Nov; Fireside chats with 90-day replays - Stock Titan

3 Investor Conferences: Sagimet Biosciences to Present Oct–Nov; Fireside chats with 90-day replays  Stock Titan

3 Investor Conferences: Sagimet Biosciences to Present Oct–Nov; Fireside chats with 90-day replays - Stock Titan

Click here to get full coverage on AI-Powered Liver Disease Analysis: Sagimet Showcases Digital Pathology Platform at Fierce Biotech Week - Stock Titan

AI-Powered Liver Disease Analysis: Sagimet Showcases Digital Pathology Platform at Fierce Biotech Week  Stock Titan

AI-Powered Liver Disease Analysis: Sagimet Showcases Digital Pathology Platform at Fierce Biotech Week - Stock Titan

Click here to get full coverage on Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewswire

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference  GlobeNewswire

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewswire

Click here to get full coverage on Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold - Seeking Alpha

Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold  Seeking Alpha

Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold - Seeking Alpha

Click here to get full coverage on Sagimet rises after denifanstat succeeds in late stage trial (SGMT) - Seeking Alpha

Sagimet rises after denifanstat succeeds in late stage trial (SGMT)  Seeking Alpha

Sagimet rises after denifanstat succeeds in late stage trial (SGMT) - Seeking Alpha

Click here to get full coverage on Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Yahoo Finance

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?  Yahoo Finance

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Yahoo Finance

Click here to get full coverage on After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)  Yahoo Finance

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

Click here to get full coverage on 33% Treatment Success: Ascletis' First-in-Class FASN Inhibitor Shows Promise in Major Acne Phase 3 Trial - Stock Titan

33% Treatment Success: Ascletis' First-in-Class FASN Inhibitor Shows Promise in Major Acne Phase 3 Trial  Stock Titan

33% Treatment Success: Ascletis' First-in-Class FASN Inhibitor Shows Promise in Major Acne Phase 3 Trial - Stock Titan

Click here to get full coverage on Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - Yahoo Finance

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know  Yahoo Finance

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Clinical-Stage Biotech Sagimet Biosciences Set for Key Investor Presentations at Major September Conferences - Stock Titan

Clinical-Stage Biotech Sagimet Biosciences Set for Key Investor Presentations at Major September Conferences  Stock Titan

Clinical-Stage Biotech Sagimet Biosciences Set for Key Investor Presentations at Major September Conferences - Stock Titan

Click here to get full coverage on 18.6% Treatment Success: Sagimet's Novel FASN Inhibitor Achieves Breakthrough in Phase 3 Acne Trial - Stock Titan

18.6% Treatment Success: Sagimet's Novel FASN Inhibitor Achieves Breakthrough in Phase 3 Acne Trial  Stock Titan

18.6% Treatment Success: Sagimet's Novel FASN Inhibitor Achieves Breakthrough in Phase 3 Acne Trial - Stock Titan

Click here to get full coverage on Insider Sellers Might Regret Selling Sagimet Biosciences Shares at a Lower Price Than Current Market Value - simplywall.st

Insider Sellers Might Regret Selling Sagimet Biosciences Shares at a Lower Price Than Current Market Value  simplywall.st

Insider Sellers Might Regret Selling Sagimet Biosciences Shares at a Lower Price Than Current Market Value - simplywall.st

Click here to get full coverage on Sagimet Biosciences Provides Clinical Trial Updates and Financial Results for Q3 2025 | SGMT Stock News - Quiver Quantitative

Sagimet Biosciences Provides Clinical Trial Updates and Financial Results for Q3 2025 | SGMT Stock News  Quiver Quantitative

Sagimet Biosciences Provides Clinical Trial Updates and Financial Results for Q3 2025 | SGMT Stock News - Quiver Quantitative

Click here to get full coverage on Is Sagimet Biosciences (SGMT) Set to Soar? - timothysykes.com

Is Sagimet Biosciences (SGMT) Set to Soar?  timothysykes.com

Is Sagimet Biosciences (SGMT) Set to Soar? - timothysykes.com

Click here to get full coverage on Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development (NASDAQ:SGMT) - Seeking Alpha

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development (NASDAQ:SGMT)  Seeking Alpha

Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development (NASDAQ:SGMT) - Seeking Alpha

Click here to get full coverage on Sagimet Biosciences Inc. Announces Participation in Upcoming Investor Conferences | SGMT Stock News - Quiver Quantitative

Sagimet Biosciences Inc. Announces Participation in Upcoming Investor Conferences | SGMT Stock News  Quiver Quantitative

Sagimet Biosciences Inc. Announces Participation in Upcoming Investor Conferences | SGMT Stock News - Quiver Quantitative

Click here to get full coverage on Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025 - Quiver Quantitative

Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025  Quiver Quantitative

Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025 - Quiver Quantitative

Click here to get full coverage on Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)  The Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail

Click here to get full coverage on Sagimet stock climbs on acne trial data (SGMT:NASDAQ) - Seeking Alpha

Sagimet stock climbs on acne trial data (SGMT:NASDAQ)  Seeking Alpha

Sagimet stock climbs on acne trial data (SGMT:NASDAQ) - Seeking Alpha

Click here to get full coverage on Sagimet Biosciences' Denifanstat Meets All Endpoints in Phase 3 Acne Clinical Trial, NDA Submission Planned in China | SGMT Stock News - Quiver Quantitative

Sagimet Biosciences' Denifanstat Meets All Endpoints in Phase 3 Acne Clinical Trial, NDA Submission Planned in China | SGMT Stock News  Quiver Quantitative

Sagimet Biosciences' Denifanstat Meets All Endpoints in Phase 3 Acne Clinical Trial, NDA Submission Planned in China | SGMT Stock News - Quiver Quantitative

Click here to get full coverage on Sagimet Biosciences stock price target raised to $35 by Citizens - Investing.com

Sagimet Biosciences stock price target raised to $35 by Citizens  Investing.com

Sagimet Biosciences stock price target raised to $35 by Citizens - Investing.com

Click here to get full coverage on Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - Stocktwits

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study  Stocktwits

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - Stocktwits

Click here to get full coverage on Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha

Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT)  Seeking Alpha

Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha

Click here to get full coverage on JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - 富途牛牛

JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26  富途牛牛

JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - 富途牛牛

Click here to get full coverage on Sagimet Biosciences Reports Successful Phase 3 Trial Results for Denifanstat in Acne Treatment and Announces Phase 1 Trial of TVB-3567 - Quiver Quantitative

Sagimet Biosciences Reports Successful Phase 3 Trial Results for Denifanstat in Acne Treatment and Announces Phase 1 Trial of TVB-3567  Quiver Quantitative

Sagimet Biosciences Reports Successful Phase 3 Trial Results for Denifanstat in Acne Treatment and Announces Phase 1 Trial of TVB-3567 - Quiver Quantitative

Click here to get full coverage on A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛

A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29  富途牛牛

A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛

Click here to get full coverage on Sagimet Biosciences Inc. SEC 10-Q Report - TradingView — Track All Markets

Sagimet Biosciences Inc. SEC 10-Q Report  TradingView — Track All Markets

Sagimet Biosciences Inc. SEC 10-Q Report - TradingView — Track All Markets

Click here to get full coverage on Sagimet Biosciences Highlights Drug Development Success - TipRanks

Sagimet Biosciences Highlights Drug Development Success  TipRanks

Sagimet Biosciences Highlights Drug Development Success - TipRanks

Click here to get full coverage on Sagimet Biosciences stock initiated with Buy rating at Clear Street - Investing.com

Sagimet Biosciences stock initiated with Buy rating at Clear Street  Investing.com

Sagimet Biosciences stock initiated with Buy rating at Clear Street - Investing.com

Click here to get full coverage on A Live Orchestra and Tightknit Cast Bring ‘Man of La Mancha’ to Vibrant Life at SGMT - suindependent.com

A Live Orchestra and Tightknit Cast Bring ‘Man of La Mancha’ to Vibrant Life at SGMT  suindependent.com

A Live Orchestra and Tightknit Cast Bring ‘Man of La Mancha’ to Vibrant Life at SGMT - suindependent.com

Click here to get full coverage on Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates  GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Click here to get full coverage on Sagimet Biosciences: A Surge or a Slip? - StocksToTrade

Sagimet Biosciences: A Surge or a Slip?  StocksToTrade

Sagimet Biosciences: A Surge or a Slip? - StocksToTrade

Click here to get full coverage on Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates  GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Click here to get full coverage on leerink partners maintains outperform rating on sagimet stock - Investing.com

leerink partners maintains outperform rating on sagimet stock  Investing.com

leerink partners maintains outperform rating on sagimet stock - Investing.com

Click here to get full coverage on Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $26 - 富途牛牛

Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $26  富途牛牛

Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $26 - 富途牛牛

Click here to get full coverage on Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - Yahoo Finance

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis  Yahoo Finance

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - Yahoo Finance

Click here to get full coverage on Sagimet Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets

Sagimet Biosciences Executives Sell Shares to Cover Tax Obligations  TradingView — Track All Markets

Sagimet Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets

Click here to get full coverage on Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans  simplywall.st

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Click here to get full coverage on Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $25  富途牛牛

Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

Click here to get full coverage on Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq

Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates  Nasdaq

Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq

Click here to get full coverage on Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025 - GlobeNewswire

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025  GlobeNewswire

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025 - GlobeNewswire

Click here to get full coverage on TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating - 富途牛牛

TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating  富途牛牛

TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Sagimet (SGMT) Advances in MASH Treatment with Denifanstat Devel - GuruFocus

Sagimet (SGMT) Advances in MASH Treatment with Denifanstat Devel  GuruFocus

Sagimet (SGMT) Advances in MASH Treatment with Denifanstat Devel - GuruFocus

Click here to get full coverage on Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative

Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025  Quiver Quantitative

Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative

Click here to get full coverage on Top Penny Stocks To Watch In April 2025 - simplywall.st

Top Penny Stocks To Watch In April 2025  simplywall.st

Top Penny Stocks To Watch In April 2025 - simplywall.st

Click here to get full coverage on Sagimet Biosciences stock price target raised to $35 by Citizens - Investing.com Nigeria

Sagimet Biosciences stock price target raised to $35 by Citizens  Investing.com Nigeria

Sagimet Biosciences stock price target raised to $35 by Citizens - Investing.com Nigeria

Click here to get full coverage on Wedbush Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $28 - 富途牛牛

Wedbush Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $28  富途牛牛

Wedbush Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $28 - 富途牛牛

Click here to get full coverage on What drives SGMT stock price - Market Liquidity Analysis & Free Wealth Planning Blueprints - earlytimes.in

What drives SGMT stock price - Market Liquidity Analysis & Free Wealth Planning Blueprints  earlytimes.in

What drives SGMT stock price - Market Liquidity Analysis & Free Wealth Planning Blueprints - earlytimes.in

Click here to get full coverage on Zanardi Fonderie S.p.A. innovates with new Savelli SGMT 2500 sand mixer - foundry-planet.com

Zanardi Fonderie S.p.A. innovates with new Savelli SGMT 2500 sand mixer  foundry-planet.com

SGMT

Price Chart

Key Statistics

Technicals

About SGMT

Latest News

SGMT News Today: China’s NMPA Accepts New Acne Drug - Meyka

Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan

Insider Sale: Executive Chairman of $SGMT Sells 37,688 Shares | SGMT Stock News - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers